Pinnacle Holdings LLC Invests $1.63 Million in The Chemours Company $CC

Key Points

• Pinnacle Holdings LLC acquired 79,337 Chemours shares worth approximately $1.63 million, while institutional investors collectively own 76.26% of the company.
• Chemours reported quarterly EPS of $0.42 and revenue of $1.59 billion, missing analyst expectations of $0.49 EPS and $1.65 billion revenue; revenue declined 1.5% year over year.
• Analysts have a consensus “Hold” rating and an average price target of $20.10, while Chemours declared a quarterly dividend of $0.0875, equivalent to a 2.2% annual yield.

Pinnacle Holdings LLC acquired a new stake in The Chemours Company (NYSE:CC - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 79,337 shares of the specialty chemicals company's stock, valued at approximately $1,628,000. Pinnacle Holdings LLC owned 0.05% of Chemours as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. Baird Financial Group Inc. purchased a new stake in shares of Chemours in the first quarter valued at about $148,000. Royal Bank of Canada raised its holdings in Chemours by 6.8% during the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company's stock worth $7,926,000 after purchasing an additional 37,382 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Chemours in the first quarter valued at about $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Chemours by 149.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company's stock valued at $593,000 after purchasing an additional 25,899 shares during the period. Finally, Empowered Funds LLC purchased a new stake in Chemours in the 1st quarter valued at approximately $403,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Trading Down 0.1%

NYSE:CC opened at $15.96 on Monday. The company has a market capitalization of $2.40 billion, a PE ratio of -8.36 and a beta of 1.43. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. The Chemours Company has a 52-week low of $10.44 and a 52-week high of $28.67. The stock has a fifty day simple moving average of $18.01 and a 200-day simple moving average of $20.05.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period in the previous year, the company posted ($2.54) earnings per share. Chemours's revenue was down 1.5% on a year-over-year basis. On average, equities research analysts expect that The Chemours Company will post 0.87 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th will be given a $0.0875 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.35 annualized dividend and a dividend yield of 2.2%. Chemours's dividend payout ratio is currently -18.32%.

Insider Transactions at Chemours

In related news, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average price of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction on Thursday, August 6th. The shares were bought at an average price of $14.94 per share, for a total transaction of $50,049.00. Following the acquisition, the chief financial officer owned 102,698 shares in the company, valued at $1,534,308.12. The trade was a 3.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 8,663 shares of company stock valued at $130,601 in the last ninety days. Corporate insiders own 0.85% of the company's stock.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CC shares. Royal Bank Of Canada cut their target price on Chemours from $26.00 to $22.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $18.00 price objective on Chemours in a research report on Monday, August 10th. JPMorgan Chase & Co. reduced their target price on Chemours from $22.00 to $15.00 and set a "neutral" rating for the company in a report on Thursday, August 13th. UBS Group restated a "neutral" rating and set a $18.00 target price (down from $29.00) on shares of Chemours in a research report on Monday, August 10th. Finally, Alembic Global Advisors reaffirmed an "overweight" rating and set a $30.00 price target on shares of Chemours in a research note on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $20.10.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source